Physician profile
Randy Daigle
NPI 1558361865
$2,692.88
in general payments reported to CMS, 2019-2025
29 companies · $446 in 2025
The $446 reported for 2025 was more than what a typical Family Medicine provider received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $186 · 2020: $304 · 2021: $556 · 2022: $419 · 2023: $544 · 2024: $239 · 2025: $446.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,229.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,228.94 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $914.16 | 2021-2025 | Vraylar |
| Amgen INC. | $400.74 | 2019-2025 | Repatha, Otezla, Repatha |
| Allergan, INC. | $179.26 | 2019-2020 | |
| Kowa Pharmaceuticals America, INC. | $140.84 | 2022-2025 | Zoryve, Livalo, Seglentis |
| Astrazeneca Pharmaceuticals LP | $120.30 | 2019-2025 | Breztri, Airsupra, Farxiga |
| Novo Nordisk INC | $97.48 | 2020-2025 | Rybelsus, Ozempic |
| Novartis Pharmaceuticals Corporation | $75.76 | 2021-2023 | |
| Sanofi-Aventis U.S. LLC | $66.04 | 2020-2022 | |
| Lilly USA, LLC | $65.34 | 2020-2025 | Jardiance, Emgality |
| Pfizer INC. | $64.05 | 2020-2025 | |
| Takeda Pharmaceuticals U.S.A., INC. | $60.20 | 2021-2024 | Trintellix |
| Axsome Therapeutics, INC. | $56.75 | 2025 | Auvelity |
| Glaxosmithkline, LLC. | $51.44 | 2019-2021 | |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $43.71 | 2025 | Caplyta |
| Abbott Laboratories | $38.37 | 2021-2023 | Freestyle Libre 2 |
Show all 29 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Exact Sciences Corporation | $33.32 | 2024-2025 | Cologuard Collection Kit |
| Sunovion Pharmaceuticals INC. | $29.93 | 2019-2022 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $28.79 | 2022-2025 | Xifaxan |
| Eisai INC. | $28.26 | 2021 | |
| Supernus Pharmaceuticals, INC. | $26.44 | 2021-2023 | Qelbree |
| Astellas Pharma US INC | $23.33 | 2021 | |
| Alkermes, INC. | $23.31 | 2023 | Aristada, Lybalvi |
| Biogen, INC. | $19.89 | 2021 | |
| Aimmune Therapeutics, INC. | $19.64 | 2024 | |
| Seqirus USA INC | $19.57 | 2022 | |
| Bayer Healthcare Pharmaceuticals INC. | $19.27 | 2023 | |
| Sanofi Pasteur INC. | $17.02 | 2023 | |
| Idorsia Pharmaceuticals US INC | $15.05 | 2023 | Quviviq |
| Boehringer Ingelheim Pharmaceuticals, INC. | $14.62 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Randy Daigle listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.